AVR Shares Anteris Technologies Global Corp.
ASX · ASXLast in our picks 2026-10-23 — not in the current list; analysis below is from that screen
Commercial transdermal technology and product development provide modest platform-driven upside.
Future value: $15.00 (+77.73%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Product development milestones may improve commercial visibility.
- ▾Below 50-day MA (-23.85%)
- ▸~78% upside to price target
Is AVR a buy right now?
Trend: AVR is trading below the 50-day average (-24.22%), RSI 55 — neutral momentum, with a 3-month return of -26.84%.
Valuation & quality: Anteris Technologies Global Corp. trades on forward P/E -3.9, price-to-book 2.25; fundamentals show net margin 0.0%, return on equity -74.7%, revenue growth 63.3% year on year.
Analyst consensus: 2 analysts have a mean 12-month price target of A$15.00 (+81.6% vs the last close; range A$13.00 – A$17.00), consensus rating “buy”.
Our screen: ACCUMULATE (score 1) — Commercial transdermal technology and product development provide modest platform-driven upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -10.50% | -2.30% | +59.40% | +12.10% | -17.90% | +6.00% | -10.00% | -23.30% |
Fundamentals
Analyst price target
Technical signals
About Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases.
Sector: Healthcare · Industry: Medical Devices · Australia · 174 employees · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.